news
Study identifies microbe-gut signalling as potential new treatment for IBD
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
List view / Grid view
Cell Therapy
webinar
Accelerating biologics discovery via antibody library and reaching IND faster with cell line development
4 April 2023 | By GenScript ProBio
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
article
The role of ABCs in lupus: insights for developing precision therapies
Researchers from the University of Pittsburgh have found that age-associated B cells (ABCs) are key drivers of lupus, a chronic autoimmune disorder that attacks the patient's own organs.
whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
whitepaper
Whitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
article
Women in STEM with Lindsey Clarke: ‘everyone has half an hour’
For International Women's Day, Drug Target Review’s Izzy Wood recently spoke to Lindsey Clarke about her experience as a woman in STEM.
news
Stopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
news
New hydrogel stem cell treatment could repair injured brain tissue
The new ‘hybrid’ hydrogel allowed researchers to safely deliver stem cells to the site of a brain injury in mice.
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
New study highlights lipid nanoparticles and mRNA could treat blindness
The researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.
whitepaper
Executive summary: Scale-up strategies for late-stage cell therapies
Discover how Catalent can help you achieve efficiencies and develop a robust, reproducible manufacturing plan for late-stage and commercial launch.
news
Novel cancer vaccine simultaneously kills and prevents brain cancer
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
